Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial.

Mey, U.J.M., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T., Jehner, P., Rauh, J., Taverna, C.J., Schmid, M., Schmidt-Hieber, M., Doerfel, S., Fischer, N., Ruefer, A., Ziske, C., Knauf, W., Cathomas, R., von Moos, R., Hitz, F., Sauter, R., Hiendlmeyer, E., Cantoni, N., Bargetzi, M., Driessen, C., 2016.

Br. J. Haematol. 176(5), 770–782. doi:10.1111/bjh.14481

Studie: BRd; Indikation: Hämoblastosen; Jahr: 2016; Veranstaltung: -; Journal: British Journal of Hematology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com